New protein structure model to inhibit cancer
July 29, 2011 By Helene Murphy in Cancer
Researchers at the University of Hertfordshire have developed a new structural model of a protein, which makes it possible to develop more effective drugs to target diseases such as cancer, heart disease and influenza.
In a paper which will be published in the Journal of Structural Biology online later this month, a research team lead by Dr. Andreas Kukol at the Universitys School of Life Sciences, describes how they have developed a new 3D model of a protein which unleashes the inhibition of the growth of cells which, unless stunted, could lead to the spread of cancer or support infections such as influenza.
Our bodies are made up of proteins and therefore they are important for the proper functioning of the body, said Dr. Kukol. Malfunction of the protein can lead to cancer. This happens when it becomes over active, so our task has been to identify inhibitors.
A research team led by Dr. Kukol developed a 3D model of the kinase IKK-β enzyme which is a protein that regulates other proteins.
This enzyme controls proteins like policeman controls traffic, said Dr. Kukol. If the policeman or the enzyme gets out of control, then there will be chaos.
The new 3D model can be used to find new inhibitors, such as organic molecules like aspirin that attach to the active site of the enzyme and make it less active thus stopping the spread of cancer or influenza.
The model is now ready for pharmaceutical companies to adopt so that they can develop more effective drugs to target these conditions. Dr. Kukol explained that the comparative modeling and computer simulation methods they used for this protein may be taken up by other research groups. In that way protein structure modelling could lead to more accurate models in the future.
Provided by University of Herfordshire
-
Scientists discover potential new target for prostate cancer treatment
Feb 13, 2011 |
not rated yet |
0
-
Worth a thousand words: Hopkins researchers paint picture of cancer-promoting culprit
Jan 04, 2008 |
not rated yet |
0
-
New cancer drug hope
Oct 26, 2006 |
not rated yet |
0
-
Three-way control of fetal heart-cell proliferation could help regenerate cardiac cells
Oct 07, 2010 |
not rated yet |
0
-
Do steaks make you big?
Jun 15, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be a term called "intestinal metaplasia" of stomach
4 hours ago
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Racial disparities in the surgical management of non-small cell lung cancer
The surgical management of non-small cell lung cancer (NSCLC) in U.S. hospitals varies widely depending on the race of the patient, according to a new study.
Cancer
1 hour ago |
not rated yet |
0
Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients ...
Cancer
1 hour ago |
not rated yet |
0
New tumour-killer shows great promise in suppressing cancers
Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.
Cancer
2 hours ago |
5 / 5 (1) |
0
New factor to control oncogene-induced senescence
An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induce ...
Cancer
2 hours ago |
not rated yet |
0
Anti-CD47 antibody may offer new route to successful cancer vaccination
(Medical Xpress)—Scientists at the School of Medicine have shown that their previously identified therapeutic approach to fight cancer via immune cells called macrophages also prompts the disease-fighting killer T cells ...
Cancer
4 hours ago |
not rated yet |
0
|
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
Study shows where scene context happens in our brain
In a remote fishing community in Venezuela, a lone fisherman sits on a cliff overlooking the southern Caribbean Sea. This man –– the lookout –– is responsible for directing his comrades on the water, ...
New immune system discovered
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
Genetic predictors of postpartum depression uncovered
Johns Hopkins researchers say they have discovered specific chemical alterations in two genes that, when present during pregnancy, reliably predict whether a woman will develop postpartum depression.
Monoclonal antibody appears effective and safe in asthma Phase IIa trial
A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to U. S. researchers.